RNA Therapeutics Market Is Expected To Generate A Revenue Of USD 22.37 Billion By 2032, Globally, At 9.4% CAGR: Verified Market Research®

(MENAFN- GlobeNewsWire - Nasdaq) Verified Market Research®, a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the RNA Therapeutics Market. Growing advancements in RNA-based drug development and increasing investments in personalized medicine drive market expansion. However, high development costs and complex regulatory frameworks present key challenges.

Lewes, Delaware, March 17, 2025 (GLOBE NEWSWIRE) -- The Global RNA Therapeutics Market Size is projected to grow at a CAGR of 9.4% from 2026 to 2032 , according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 10.9 Billion in 2024 and is expected to reach USD 22.37 Billion by the end of the forecast period.

RNA-based therapies are transforming modern medicine, offering targeted treatment options for various diseases, including cancer, genetic disorders, and infectious diseases. The market is experiencing rapid growth due to continuous advancements in synthetic biology, increased R&D funding, and rising regulatory approvals. The success of mRNA vaccines has accelerated the adoption of RNA therapeutics, positioning the market for strong future expansion.

Key Highlights of the Market Report :

• Market Size & Growth Projections : Detailed insights into the global RNA therapeutics market valuation and projected CAGR.
• Technology Trends : Advances in RNA-based drug delivery systems, including lipid nanoparticles and polymer-based carriers.
• Market Drivers & Challenges : Analysis of factors boosting market growth and key barriers limiting expansion.
• Competitive Landscape : Profiles of leading companies and emerging biotech firms in the RNA therapeutics space.
• Regulatory Insights : Impact of evolving FDA and EMA guidelines on market dynamics.
• Regional Analysis : Key markets driving growth, including North America, Europe, and Asia-Pacific.

Why This Report Matters?

This report provides a strategic roadmap for biotech companies, pharmaceutical firms, and investors looking to capitalize on the RNA therapeutics revolution. It delivers actionable insights into market trends, competitive strategies, and regulatory developments, helping stakeholders make informed business decisions.

Who Should Read This Report?

• Pharmaceutical & Biotech Companies exploring RNA-based drug development.
• Investors & Venture Capitalists seeking emerging opportunities in the biotech sector.
• Healthcare Professionals & Researchers involved in RNA-based therapeutics and drug delivery innovations.
• Regulatory Agencies & Policymakers assessing the impact of RNA therapeutics on healthcare and policy frameworks.

For more information or to purchase the report, please contact us at :

Browse in-depth TOC on “ Global RNA Therapeutics Market Size ”

202 - Pages

126 – Tables

37 – Figures

Report Scope

REPORT ATTRIBUTES	DETAILS
HISTORICAL YEAR	2023
BASE YEAR	2024
ESTIMATED YEAR	2025
PROJECTED YEARS	2026–2032
UNIT	Value (USD Billion)
KEY COMPANIES PROFILED	Moderna, BioNTech SE, Pfizer, Inc., CureVac N.V., Arcturus Therapeutics Holdings, Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Dicerna Pharmaceuticals, Sarepta Therapeutics, Translate Bio, Regeneron Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics plc, Intellia Therapeutics, and Strand Therapeutics.
SEGMENTS COVERED	By Product, By Type, By Application, By Distribution Channel, and By Geography.
CUSTOMIZATION SCOPE	Free report customization (equivalent up to 4 analyst's working days) with purchase. Addition or alteration to country, regional & segment scope

Global RNA Therapeutics Market Overview

Key Market Drivers

Rising Investment in RNA-based Drug Development: The influx of capital from pharmaceutical corporations and biotechnology companies is expediting research on RNA therapies. Governments and private investors are investing significant cash to research novel RNA-based therapeutics for ailments such as cancer, genetic problems, and uncommon diseases. The flood of investment is accelerating clinical studies and regulatory approvals, generating profitable growth prospects for market participants aiming to leverage the forthcoming advancements in precision medicine.

Breakthroughs in RNA Delivery Systems: Innovations in lipid nanoparticles (LNPs), polymeric carriers, and exosome-based delivery mechanisms are addressing conventional issues related to RNA stability and transport. These developments are improving the bioavailability and effectiveness of RNA therapies, facilitating more precise and prolonged drug delivery. The integration of next-generation platforms by drug developers is enhancing the commercial feasibility of RNA treatments, positioning them as a transformational element in personalized medicine.

Expanding Applications in Infectious Diseases and Oncology: The remarkable effectiveness of mRNA vaccinations has intensified interest in RNA-based therapeutics beyond COVID-19. Pharmaceutical companies are utilizing RNA platforms to create vaccines for influenza, HIV, and other viral diseases. Moreover, RNA therapies demonstrate encouraging outcomes in cancer immunotherapy through the modulation of gene expression and the augmentation of immune responses. The robust clinical pipelines in oncology and infectious diseases position the market for enduring long-term growth.

To Purchase a Comprehensive Report Analysis :

Market Restraints Hindering the Market Growth

High Development and Manufacturing Costs: RNA treatments necessitate advanced synthesis, purification, and storage methodologies, resulting in considerable production expenses. The large-scale production of RNA-based pharmaceuticals requires substantial investments in specialized infrastructure, hence restricting the participation of smaller biotechnology companies. Moreover, rigorous regulatory mandates for innovative RNA therapeutics extend development times, presenting a costly obstacle for organizations attempting to attain commercial viability.

Challenges in Stability and Delivery: RNA molecules possess intrinsic instability and are susceptible to swift destruction in biological contexts. Efficient RNA drug delivery necessitates sophisticated formulation procedures to guarantee controlled release and targeted efficacy. Although advancements in lipid nanoparticles and chemical modifications are addressing these problems, achieving long-term stability and consistent therapeutic efficacy continues to be a significant obstacle for the broad adoption of RNA therapies.

Regulatory Uncertainty and Intellectual Property Barriers: The changing regulatory environment for RNA-based therapeutics poses a challenge for market participants in navigating approval processes. Regulatory bodies such as the FDA and EMA are continuously modifying standards for RNA therapies, resulting in delays in market entrance. Moreover, fierce patent competition among biotechnology businesses hinders innovation due to licensing intricacies and the possibility of intellectual property issues. The regulatory and legal uncertainty hinders commercialization and elevates risks for new entrants.

Geographical Dominance:

North America Leads the RNA Therapeutics Market with Strong R&D and Regulatory Support

North America leads the RNA therapies market, propelled by strong biotechnology innovation, substantial research and development spending, and advantageous regulatory environments. The United States spearheads advancements in mRNA technology through prominent companies such as Moderna and BioNTech. Robust support from the NIH and FDA expedites approvals, while university partnerships drive novel discoveries. As the adoption of RNA-based therapeutics increases in oncology and infectious illnesses, North America continues to be the focal point of market expansion.

Key Players

The“Global RNA Therapeutics Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Moderna, BioNTech SE, Pfizer, Inc., CureVac N.V., Arcturus Therapeutics Holdings, Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Dicerna Pharmaceuticals, Sarepta Therapeutics, Translate Bio, Regeneron Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics plc, Intellia Therapeutics, and Strand Therapeutics.

RNA Therapeutics Market Segment Analysis

Based on the research, Verified Market Research has segmented the market into Product, Type, Application, Distribution Channel, and Geography.

• RNA Therapeutics Market, by Product
  • Vaccines
  • Drugs
    
• RNA Therapeutics Market, by Type
  
  • mRNA Therapeutics
  • RNA Interference
  • Antisense Oligonucleotides

• RNA Therapeutics Market, by Application
  • Cardiovascular
  • Oncology
  • Dermatology
  • Musculoskeletal
  • Wound Healing
  • Ophthalmology
  • Neurology
  • Others
    
• RNA Therapeutics Market, by Distribution Channel
  
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

• RNA Therapeutics Market, by Geography
  • North America
    • U.S
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • ROW
    • Middle East & Africa
    • Latin America

Browse Related Reports:

Global RNA Analysis Market Size By Product Type (Reagents/Consumables, Instruments), By Technology (Microarrays, Sequencing, Polymerase Chain Reaction (PCR)), By Application (Clinical Diagnostics, Drug Discovery, Toxicogenomic), By End-Uuser (Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Centers), By Geography, And Forecast

Global Inorganic Pyrophosphatase Market Size By End-user (Pharmaceutical And Biotech Companies, Contract Research Organizations (CROs)), By Type (Recombinant Inorganic Pyrophosphatase, Thermostable Inorganic Pyrophosphatase), By Sales Channel (Online, Distributors), By Source (Escherichia Coli, Yeast), By Application (Orthophosphate Production, RNA In Vitro Transcription (IVT)), By Geography, And Forecast

Global Nucleic Acid Isolation And Purification Market Size By End-User (Hospitals and Diagnostic Centers, Academic Research Institutes, Pharma and Biotech Companies, Contract Research Organizations (CROs)), Method (Column-based Isolation, Magnetic Bead-based Isolation), Nucleic Acid Type (Genomic DNA Isolation, Plasmid DNA Isolation, RNA Isolation, MicroRNA (miRNA) Isolation), By Geography, And Forecast

Global DNA And RNA Banking Services Market Size By Service (Transportation Service, Processing Service, Storage Service), By Specimen Type (Blood, Saliva), By Applications (Therapeutics, Drug Discovery & Clinical Research, Clinical Diagnostics), By End User (Hospitals & Diagnostic Centers, Academic Research, Pharmaceutical & Biotechnology Companies), By Geography, And Forecast

Visualize RNA Therapeutics Market using Verified Market Intelligence -:

Verified Market Intelligence is our BI Enabled Platform for narrative storytelling in this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us

Verified Market Research® stands at the forefront as a global leader in Research and Consulting, offering unparalleled analytical research solutions that empower organizations with the insights needed for critical business decisions. Celebrating 10+ years of service, VMR has been instrumental in providing founders and companies with precise, up-to-date research data.

With a team of 500+ Analysts and subject matter experts, VMR leverages internationally recognized research methodologies for data collection and analyses, covering over 15,000 high impact and niche markets. This robust team ensures data integrity and offers insights that are both informative and actionable, tailored to the strategic needs of businesses across various industries.

VMR's domain expertise is recognized across 14 key industries, including Semiconductor & Electronics, Healthcare & Pharmaceuticals, Energy, Technology, Automobiles, Defense, Mining, Manufacturing, Retail, and Agriculture & Food. In-depth market analysis cover over 52 countries, with advanced data collection methods and sophisticated research techniques being utilized. This approach allows for actionable insights to be furnished by seasoned analysts, equipping clients with the essential knowledge necessary for critical revenue decisions across these varied and vital industries.

Verified Market Research® is also a member of ESOMAR, an organization renowned for setting the benchmark in ethical and professional standards in market research. This affiliation highlights VMR's dedication to conducting research with integrity and reliability, ensuring that the insights offered are not only valuable but also ethically sourced and respected worldwide.

Read More About Verified Market Research:-

CONTACT: Contact Us Mr. Edwyne Fernandes Verified Market Research® US: +1 (650)-781-4080 US Toll Free: +1 (800)-782-1768 Email: ... Web: Follow Us: LinkedIn | Twitter | Threads | Instagram | Facebook SOURCE – Verified Market Research®

MENAFN17032025004107003653ID1109323407